Sun Pharma announced on September 28 the signing of an exclusive agreement with US-based LIB Therapeutics covering manufacture, commercialisation and global licensing of Lerodalcibep, an advanced medication designed to control bad cholesterol, across all markets except the United States and China.
Lerodalcibep is a once-monthly PCSK9 inhibitor used to lower low-density lipoprotein cholesterol (LDL-C) in adult patients with hypercholesterolaemia and mixed dyslipidaemia.
PCSK9 inhibitors work by blocking the PCSK9 protein, thereby helping reduce levels of LDL, commonly referred to as bad cholesterol.
LIB Therapeutics will receive upfront payments as well as future milestone payments, news agency PTI reported citing the terms of the deal.
Also read | CDSCO steps up scrutiny of pharma drugs containing narcotic substances
The company will also be entitled to royalties linked to net sales across the licensed territories. Financial details beyond these terms have not been disclosed.
The drug secured marketing authorisation from the European Commission on September 21, 2026, where it will be sold under the brand name Lyrokaul. In the US, the drug has received approval from the Food and Drug Administration under the name Lerochol.
Sun Pharma said the transaction will add to its Innovative Medicines portfolio by giving it access to the PCSK9 market outside the US and China, valued at $3.7 billion and expanding at a 38 per cent CAGR.
Europe represents a substantial portion of this opportunity. The region contributed $2.9 billion to the market in MAT Q2 2026.
Sun Pharma Managing Director Kirti W Ganorkar said the once-monthly dosing regimen could make treatment more convenient because of the drug's strong LDL-C reduction, small-volume injection and ability to be stored for six months at ambient temperature.
Also read | Rs 78,400 vs Rs 7,750 medicine: Novartis, Eli Lilly oppose bid to cut breast cancer drug prices in
He said the agreement would further strengthen Sun Pharma's presence in Innovative Medicines, particularly in cardiovascular care, while allowing the company to widen access to the treatment in markets covered by its exclusive rights.
Sun Pharma will also take charge of seeking regulatory clearances in licensed markets where Lerodalcibep has not yet secured approval.
